CA2388530A1 - Melange therapeutique d'inhibiteurs de hmg-coa reductase - Google Patents

Melange therapeutique d'inhibiteurs de hmg-coa reductase Download PDF

Info

Publication number
CA2388530A1
CA2388530A1 CA002388530A CA2388530A CA2388530A1 CA 2388530 A1 CA2388530 A1 CA 2388530A1 CA 002388530 A CA002388530 A CA 002388530A CA 2388530 A CA2388530 A CA 2388530A CA 2388530 A1 CA2388530 A1 CA 2388530A1
Authority
CA
Canada
Prior art keywords
hmg
coa reductase
arginine
reductase inhibitor
pravastatin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002388530A
Other languages
English (en)
Inventor
Wayne H. Kaesemeyer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nitrosystems Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2388530A1 publication Critical patent/CA2388530A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne des mélanges thérapeutiques de statines, seules ou combinées à la L-arginine.
CA002388530A 1999-10-19 2000-10-19 Melange therapeutique d'inhibiteurs de hmg-coa reductase Abandoned CA2388530A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42081699A 1999-10-19 1999-10-19
US09/420,816 1999-10-19
PCT/US2000/041304 WO2001028499A2 (fr) 1999-10-19 2000-10-19 Melange therapeutique d'inhibiteurs de hmg-coa reductase

Publications (1)

Publication Number Publication Date
CA2388530A1 true CA2388530A1 (fr) 2001-04-26

Family

ID=23667961

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002388530A Abandoned CA2388530A1 (fr) 1999-10-19 2000-10-19 Melange therapeutique d'inhibiteurs de hmg-coa reductase

Country Status (5)

Country Link
EP (1) EP1225885A4 (fr)
AU (1) AU2116201A (fr)
CA (1) CA2388530A1 (fr)
MX (1) MXPA02004021A (fr)
WO (1) WO2001028499A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6425881B1 (en) * 1994-10-05 2002-07-30 Nitrosystems, Inc. Therapeutic mixture useful in inhibiting lesion formation after vascular injury
CA2367002A1 (fr) 1999-03-19 2000-09-28 Michael A. Moskowitz Renforcement de la biodisponibilite des medicaments dans le cerveau
USRE44578E1 (en) 2000-04-10 2013-11-05 Teva Pharmaceutical Industries, Ltd. Stable pharmaceutical compositions containing 7-substituted-3,5-dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids
EP1865945A4 (fr) * 2005-03-11 2008-05-21 Hong Kong Nitric Oxide Ltd Combinaison de traitement pour les troubles endotheliaux, l'angine et le diabete
CN105246472B (zh) * 2013-03-15 2018-10-12 武汉朗来科技发展有限公司 含有鸟氨酸和/或门冬氨酸的组合物及其应用
WO2014139469A1 (fr) * 2013-03-15 2014-09-18 Wuhan Qr Science And Technology Development Co. Compositions comprenant de l'ornithine ou de l'aspartate et utilisations associées

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5447922A (en) * 1994-08-24 1995-09-05 Bristol-Myers Squibb Company α-phosphonosulfinic squalene synthetase inhibitors
US5968983A (en) * 1994-10-05 1999-10-19 Nitrosystems, Inc Method and formulation for treating vascular disease

Also Published As

Publication number Publication date
EP1225885A2 (fr) 2002-07-31
AU2116201A (en) 2001-04-30
MXPA02004021A (es) 2004-08-23
EP1225885A4 (fr) 2004-04-21
WO2001028499A2 (fr) 2001-04-26
WO2001028499A3 (fr) 2001-10-04

Similar Documents

Publication Publication Date Title
AU744813B2 (en) Method and formulation for treating vascular disease
US6425881B1 (en) Therapeutic mixture useful in inhibiting lesion formation after vascular injury
Stamler et al. Nitric oxide regulates basal systemic and pulmonary vascular resistance in healthy humans.
EP1139753B1 (fr) Preparations destinees au traitement de maladies et procedes s'y rapportant
US5767160A (en) Method and formulation of stimulating nitric oxide synthesis
US20030114515A1 (en) Therapeutic mixture of HMG-COA reductase inhibitors
Lyons Impairment and restoration of nitric oxide-dependent vasodilation in cardiovascular disease
WO2002017898A2 (fr) Compositions et procedes visant a induire une vasorelaxation
CA2388530A1 (fr) Melange therapeutique d'inhibiteurs de hmg-coa reductase
Gruhn et al. Tetrahydrobiopterin improves endothelium-dependent vasodilation in nitroglycerin-tolerant rats
US8399518B2 (en) Administration of 3,5-diiodothyropropionic acid for stimulating weight loss, and/or lowering triglyceride levels, and/or treatment of metabolic syndrome
CA2361575A1 (fr) Formulations a base de l-arginine utilisees dans le traitement de maladies, et leurs procedes d'utilisation
WO2002030425A1 (fr) Medicaments pour la prevention ou le traitement de complications du diabete
US20090093542A1 (en) Copper antagonist compositions
EP1671630A2 (fr) Formulations basées sur l-arginine pour le traitment des maladies et méthodes utilisants les memes
WO2005027887A2 (fr) Procedes et compositions permettant d'ameliorer la fonction endotheliale
EP1377284A1 (fr) Formulations d'arginine liberation lente
US20050159490A1 (en) Method to treat chronic heart failure and/or elevated cholesterol levels
d'Uscio et al. Role of Nitric Oxide in the Microcirculation
MXPA99009243A (en) Method and formulation for treating vascular disease
US20090093506A1 (en) Copper antagonist compositions
Yang et al. L-Arginine and Ischemia-Reperfusion Injury
McCafferty et al. The Physiological and Pathophysiological Effects of Nitric Oxide on the Intestinal Circulation
Corson Nitric Oxide in Cardiovascular Biology and Pathophysiology

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead